Cellebrite DI Ltd. $CLBT Shares Sold by Clal Insurance Enterprises Holdings Ltd

Clal Insurance Enterprises Holdings Ltd trimmed its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 11.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,473,014 shares of the company’s stock after selling 440,000 shares during the quarter. Clal Insurance Enterprises Holdings Ltd owned about 1.45% of Cellebrite DI worth $62,618,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in CLBT. CWM LLC lifted its holdings in shares of Cellebrite DI by 57.0% in the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after buying an additional 889 shares during the period. SkyView Investment Advisors LLC lifted its holdings in shares of Cellebrite DI by 2.6% in the 2nd quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock valued at $597,000 after buying an additional 970 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in shares of Cellebrite DI by 17.8% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 12,216 shares of the company’s stock valued at $220,000 after buying an additional 1,850 shares during the period. Seelaus Asset Management LLC lifted its holdings in shares of Cellebrite DI by 11.9% in the 4th quarter. Seelaus Asset Management LLC now owns 18,850 shares of the company’s stock valued at $340,000 after buying an additional 2,000 shares during the period. Finally, Advisory Services Network LLC acquired a new stake in shares of Cellebrite DI in the 3rd quarter valued at approximately $40,000. 45.88% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CRO Marcus Jewell sold 12,658 shares of Cellebrite DI stock in a transaction on Monday, May 18th. The stock was sold at an average price of $12.77, for a total value of $161,642.66. Following the transaction, the executive owned 440,101 shares in the company, valued at approximately $5,620,089.77. This trade represents a 2.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 13,269 shares of company stock worth $169,592 in the last 90 days. 5.70% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

CLBT has been the subject of several research analyst reports. Weiss Ratings raised Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. Needham & Company LLC dropped their price objective on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Wall Street Zen raised Cellebrite DI from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Finally, DA Davidson initiated coverage on Cellebrite DI in a research note on Wednesday, May 27th. They issued a “buy” rating and a $20.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $21.40.

Cellebrite DI Price Performance

NASDAQ CLBT opened at $12.84 on Friday. Cellebrite DI Ltd. has a 1-year low of $11.02 and a 1-year high of $19.98. The company has a market capitalization of $3.20 billion, a P/E ratio of 45.86, a PEG ratio of 1.59 and a beta of 1.17. The business has a 50 day moving average price of $13.23 and a 200 day moving average price of $15.05.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.